Get the Stockscreener App
2.205
4.25%
0.085
Black Diamond Therapeutics Inc stock is traded at $2.205, with a volume of 171.33K.
It is up +4.25% in the last 24 hours and down -0.45% over the past month.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
See More
Previous Close:
$2.12
Open:
$2.14
24h Volume:
171.33K
Relative Volume:
0.21
Market Cap:
$125.63M
Revenue:
$70.00M
Net Income/Loss:
$21.50M
P/E Ratio:
6.0777
EPS:
0.3628
Net Cash Flow:
$21.35M
1W Performance:
+1.38%
1M Performance:
-0.45%
6M Performance:
-30.28%
1Y Performance:
+28.49%
1-Day Range:
$2.14
$2.23
1-Week Range:
$2.07
$2.28
52-Week Range:
$1.195
$4.94
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Name
Black Diamond Therapeutics Inc
Sector
Industry
Phone
617-417-5868
Address
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Compare BDTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
2.205 | 120.79M | 70.00M | 21.50M | 21.35M | 0.3628 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.29 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.81 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
706.55 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.61 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
288.86 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-25 | Resumed | Piper Sandler | Overweight |
| Oct-16-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Jul-31-24 | Initiated | Raymond James | Outperform |
| Jul-14-23 | Initiated | Piper Sandler | Overweight |
| Jun-30-23 | Upgrade | Stifel | Hold → Buy |
| Jun-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-29-22 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-22-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jan-07-21 | Initiated | Wedbush | Outperform |
| Nov-24-20 | Initiated | Berenberg | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | Canaccord Genuity | Buy |
| Feb-24-20 | Initiated | Cowen | Outperform |
| Feb-24-20 | Initiated | JP Morgan | Overweight |
| Feb-24-20 | Initiated | Jefferies | Buy |
View All
Black Diamond Therapeutics Inc Stock (BDTX) Latest News
Black Diamond Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier - Finviz
Published on: 2026-03-07 03:01:03 - baoquankhu1.vn
Black Diamond Therapeutics Teases Next-Quarter PFS Data for Silevertinib at TD Cowen Conference - MarketBeat
Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug? - MSN
Downgrade Watch: Whats the profit margin of Black Diamond Therapeutics IncWeekly Market Summary & Real-Time Stock Entry Alerts - baoquankhu1.vn
BDTX: Silevertinib demonstrates robust efficacy in NSCLC and is advancing to pivotal GBM trials - TradingView
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors - Quantisnow
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Black Diamond Therapeutics Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Clinical-stage oncology firm Black Diamond sets 3 investor events - Stock Titan
Revenue Check: Is Black Diamond Therapeutics Inc a strong growth stock2025 Investor Takeaways & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
BDTX PE Ratio & Valuation, Is BDTX Overvalued - Intellectia AI
Hedge Fund Bets: Is Black Diamond Therapeutics Inc a strong growth stock2025 Key Highlights & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Black Diamond Therapeutics (BDTX) Expected to Announce Quarterly Earnings on Thursday - Defense World
BDTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BDTX SEC FilingsBlack Diamond Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Will Black Diamond Therapeutics Inc. benefit from AI trendsTrade Exit Summary & High Yield Stock Recommendations - mfd.ru
Breakout Zone: What hedge funds are buying Black Diamond Therapeutics IncJuly 2025 Pullbacks & Intraday High Probability Alerts - baoquankhu1.vn
Is Black Diamond Therapeutics Inc. stock undervalued vs historical averagesTrade Entry Summary & Daily Profit Maximizing Trade Tips - mfd.ru
Dividend Watch: Does Capitol Investment Corp VI Debt Equity Composite Units align with a passive investing strategyMarket Movement Recap & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Black Diamond Therapeutics (NASDAQ:BDTX) Stock Price Up 0.5%Here's Why - MarketBeat
Black Diamond Therapeutics (NASDAQ:BDTX) Stock Price Up 0.5% – Here’s Why - Defense World
Dip Buying: Will Black Diamond Therapeutics Inc benefit from AI trendsJuly 2025 Technicals & Reliable Entry Point Alerts - baoquankhu1.vn
Vestal Point holds 1.5% of Black Diamond Therapeutics (BDTX) stock - Stock Titan
Portfolio Update: Is AEVAW a strong candidate for buy and holdMarket Weekly Review & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Does Black Diamond Therapeutics Inc. outperform in volatile marketsEarnings Summary Report & Community Consensus Stock Picks - mfd.ru
Why Black Diamond Therapeutics Inc. stock is popular among millennialsJuly 2025 Review & AI Enhanced Execution Alerts - mfd.ru
BDTX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Can Black Diamond Therapeutics Inc. reach all time highs this year2025 Valuation Update & Weekly High Potential Stock Alerts - mfd.ru
What is Black Diamond Therapeutics Inc. s revenue forecast2025 Risk Factors & High Accuracy Buy Signal Tips - mfd.ru
Black Diamond Therapeutics, Inc. (BDTX) price target trimmed as Piper updates biotech models and 2026 catalyst tracker - MSN
Will Black Diamond Therapeutics Inc. stock sustain high P E ratiosExit Point & Daily Profit Focused Screening - mfd.ru
Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker - Finviz
Dow Update: What is Black Diamond Therapeutics Incs revenue forecast2025 Biggest Moves & Daily Growth Stock Investment Tips - baoquankhu1.vn
What’s the profit margin of Black Diamond Therapeutics Inc.Take Profit & Safe Entry Zone Tips - mfd.ru
Convergent Therapeutics Appoints Elizabeth L. Montgomery Chief People Officer - BioSpace
How much upside does Black Diamond Therapeutics Inc. haveJuly 2025 Big Picture & Detailed Earnings Play Strategies - mfd.ru
Entry Recap: Can Black Diamond Therapeutics Inc maintain sales growthRate Cut & Precise Swing Trade Alerts - baoquankhu1.vn
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aug Reactions: Does Black Diamond Therapeutics Inc outperform in volatile markets2025 Key Highlights & Expert Approved Trade Ideas - baoquankhu1.vn
Growth Review: Is Black Diamond Therapeutics Inc stock good for income investorsEarnings Beat & High Conviction Trade Alerts - baoquankhu1.vn
Is Black Diamond Therapeutics (BDTX) stock outpacing its medical peers this year? - MSN
Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Aug Patterns: Does Black Diamond Therapeutics Inc outperform in volatile marketsJuly 2025 Earnings & Precise Swing Trade Alerts - baoquankhu1.vn
Market Review: Whats the profit margin of Black Diamond Therapeutics IncEarnings Performance Report & Real-Time Buy Signal Notifications - baoquankhu1.vn
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Down 39.9% in December - Defense World
Piper Sandler Maintains Rating but Lowers Price Target for BDTX | BDTX Stock News - GuruFocus
Declining Stock and Solid Fundamentals: Is The Market Wrong About Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)? - Yahoo Finance
Growth Value: What is the long term forecast for MPLX LP Limited Partnership stockJuly 2025 Big Picture & Weekly Chart Analysis and Guides - baoquankhu1.vn
Black Diamond Therapeutics Inc Stock (BDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):